Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Upjohn Depo-Provera

Executive Summary

Center for Drugs and Biologics is recommending that Commissioner Young deny Upjohn's Aug. 4 request to reopen the record in the Depo-Provera hearing for additional evidence and to allow oral argument. In a letter to the commissioner, the center asserts that Upjohn's petition should be denied because the firm "has set forth no facts that establish the importance, and . . . even the relevance of the submissions that it proposes to be considered." Upjohn is requesting that the record be reopened to receive data from an interim report on a World Health Organization study of Depo-Provera, a new historical study on the association between Depo-Provera and breast cancer, a post-marketing surveillance study of Depo-Provera in the U.K., and a report by the Expert Committee on Reproductive Physiology.

You may also be interested in...

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts